Where primary CNS lymphoma treatment is heading
Primary CNS lymphoma · Updated Nov 14, 2026
Primary central nervous system lymphoma (PCNSL) is an aggressive lymphoma that starts in the brain, spinal cord, eyes or spinal fluid, without disease elsewhere. About 1,500 Americans are diagnosed each year, most over 60. Treatment starts with high-dose methotrexate-based chemotherapy, followed by consolidation to prevent relapse. A large 2026 trial confirmed stem-cell transplant as the best consolidation for fit patients, and BTK inhibitor pills that reach the brain are moving toward approval and into first-line treatment.
- 116studies open or running
- 6phase 3 trials
- 265papers published this year
-
Now
Nov 2026
Transplant is the best consolidationHappened 78% 3-year progression-free
After MATRix induction, transplant gave 78% 3-year progression-free survival vs 51% with further chemotherapy.
78%: 3-year progression-free with transplant, vs 51%.
Low-dose radiation as an alternativeHappened 78.7% 2-year progression-free
Adding low-dose brain radiation to chemotherapy raised 2-year progression-free survival to 78.7% vs 54%, without measurable harm to thinking.
78.7%: 2-year progression-free with low-dose radiation, vs 54%.
BTK inhibitors work in the brainHappened 73% response rate
Across 40 studies, BTK inhibitors shrank CNS lymphoma in 73% of patients.
73%: pooled response rate.
-
6 months
by May 2027
FDA decision on tirabrutinibLikely 67% response rate
The FDA is due to decide by December 18, 2026, on tirabrutinib for relapsed PCNSL (67% response rate).
67%: response rate.
-
12 months
by Nov 2027
Confirming tirabrutinibPossible
Ono's IGNITE (132 people) compares tirabrutinib with rituximab-temozolomide; due December 2027.
-
3 years
by late 2029
Less intensive inductionPossible
OptiMATe (331 people) tests shorter induction; due June 2028.
BTK inhibitors in first-line treatmentPossible 87.1% complete response (phase 2)
A Chinese phase 3 adds orelabrutinib to first-line chemotherapy (215 people, due September 2028).
87.1%: complete response after induction.
CAR T cellsLong shot
A liso-cel trial adds CAR T cells to first-line treatment (65 people, due January 2028).
-
5 years
by late 2031
Transplant for older patientsPossible 78% 3-year progression-free (under 70)
PRIMA-CNS (340 people) tests adjusted-dose transplant in older patients; due August 2029.
78%: 3-year progression-free with transplant, vs 51%.
The research paths
BTK inhibitors
67% response rateDetails and 3 trialsHide
Brain-penetrating pills for relapse and, increasingly, first-line treatment.
WatchTirabrutinib FDA decision; IGNITE.
- Tirabrutinib vs rituximab-temozolomide (IGNITE)Ono Pharmaceutical · 132 people · enrolling Dec 2027
- Orelabrutinib with teniposide, rituximab and methotrexateHuashan Hospital · 215 people · enrolling Sep 2028
- Lenalidomide and ibrutinib maintenance (LOC-R01)Institut Curie · 118 people · fully enrolled Feb 2035
Consolidation strategy
78% 3-year progression-freeDetails and 2 trialsHide
Transplant, low-dose radiation, or maintenance after induction.
WatchPRIMA-CNS; OptiMATe.
Cell therapy
Details and 1 trialsHide
CAR T cells for relapsed and high-risk disease.
WatchLiso-cel first-line trial.
Borrowed from other cancers
From CLL and other B-cell lymphomas
Tirabrutinib and other BTK inhibitors
Under FDA review
BTK inhibitors developed for systemic lymphomas that also cross into the brain.
From Diffuse large B-cell lymphoma
Liso-cel
Phase 2
A CD19 CAR T-cell therapy approved for lymphomas outside the brain.
From Multiple myeloma
Lenalidomide
Phase 2
An immune-modulating pill tested with ibrutinib for maintenance.
Open to join now
-
Relapsed PCNSL
Tirabrutinib
Locations and eligibility → -
Older adults with new PCNSL
Adjusted transplant
Locations and eligibility → -
New PCNSL
Orelabrutinib with chemotherapy
Locations and eligibility → -
New PCNSL
Liso-cel CAR T cells
Locations and eligibility →
See every recruiting PCNSL trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Transplant beats chemotherapy as consolidation
MATRix/IELSG43, The Lancet.
FDA accepts tirabrutinib application
PROSPECT; decision due December 2026.
Standard treatment today
- New, fit for intensive treatmentHigh-dose methotrexate-based induction (such as MATRix), then stem-cell transplant.
- New, older or frailMethotrexate-based chemotherapy, then maintenance or low-dose radiation; transplant in selected patients.
- RelapsedIbrutinib, lenalidomide, other chemotherapy, radiation, or transplant if not done before.
- Eye involvementInjections into the eye or eye radiation, plus systemic treatment.
How to read this page, and sourcesHow to read this page, and sources
- PCNSL is different from lymphoma that spreads to the brain from elsewhere (secondary CNS lymphoma), though some studies include both.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See PCNSL trials recruiting now →